VOYAGER-PAD finds no excess mortality or amputation risk with paclitaxel-coated devices When a 2018 meta-analysis of 28 trials reported "a significant relationship" between exposure to paclitaxel via a drug-eluting stent used to treat peripheral artery disease (PAD) and excess mortality, the FDA responded by first issuing a warning letter, followed by a second letter urging
Lipid-lowering therapy use low, LDL elevated in patients with PAD healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Going Against Guidelines—Nearly 50% of PAD Patients Do Not Receive Statin Therapy physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.